Aderbasib
 | |
| Systematic (IUPAC) name | |
|---|---|
| methyl (6S,7S)-7-(hydroxycarbamoyl)-6-[(4-phenyl-1-piperazinyl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylate | |
| Clinical data | |
| |
| Oral | |
| Identifiers | |
| 791828-58-5 | |
| None | |
| PubChem | CID 16070111 |
| ChemSpider | 17229620 |
| ChEMBL | CHEMBL1376060 |
| Chemical data | |
| Formula | C21H28N4O5 |
| 416.47 g·mol−1 | |
|
SMILES
| |
| |
Aderbasib (INN/USAN, codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation.[1] Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells.[2] Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.[3][4]
References
- ↑ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). Ama-assn.org. Retrieved 2012-10-13.
- ↑ "Aderbasib | CAS#791828-58-5". MedKoo. Retrieved 2012-10-13.
- ↑ Incyte (2011-09-19). "UBS 2011 Global Life Sciences Conference". Retrieved 2013-02-13.
- ↑ "Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs" (Press release). BusinessWire. 2011-10-27. Retrieved 2013-02-13.